Hvilken er prisen på Gamida Cell Ltd. (GMDA)

Prisen på Gamida Cell Ltd. (GMDA) er $0.0327

Hva er markedsverdien på Gamida Cell Ltd. (GMDA)

Markedsverdien på Gamida Cell Ltd. (GMDA) er $4.34M

Gamida Cell Ltd. (GMDA) Prishistorikk

Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.

År	Ytelse
2025	117.76%
2024	-95.28%
2023	-75.22%
2022	-48.32%
2021	-71.87%
2020	84.95%
2019	-55.53%
2018	0.00%

År

Ytelse

2025

117.76%

2024

-95.28%

2023

-75.22%

2022

-48.32%

2021

-71.87%

2020

84.95%

2019

-55.53%

2018

0.00%

Selskap	Aksjepris	Endring 1år%	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$505.24	28.63%	US
Argenx SE ARGX.US	$846.09	29.41%	NL
Lonza Group AG LONN.SW	$731.69	6.47%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.40%	KR
UCB S.A. UCB.BR	$251.82	11.75%	BE

Selskap

Aksjepris

Endring 1år%

Land